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Toll-like receptors (TLRs) are members of the integral glycoproteins family, 
which are consist of intracellular and endoplasmic domains. TLRs are widely 
distributed in body tissues and expressed by immune and nonimmune cells. They 
are able to identify pathogens that cause cell injury and distinguish them from 
harmless microbes, and pathogenic nucleic acids as their binding ligand. Upon 
binding to their ligands, TLRs first underwent conformational changes; either 
forming homodimers or heterodimers, starting signaling pathways involve adaptor 
molecules utilization and then signal transduction through either myeloid dif-
ferential (MyD)-88 dependent or independent pathways. Ending with activation of 
several transcription factors (TF) and release of pro-inflammatory cytokines (CK) 
and Type I interferons (IFN) and initiation of inflammation. TLRs are involved in 
almost all-inflammatory processes due to underlying disorders and diseases, which 
made them interesting targets for therapeutic development, via the synthesis of 
different agonists, antagonists, and even naturalized antibodies.
Keywords: Innate immune response, Toll-like receptors, Myeloid differential88, 
Cluster differential 14, Lymphocyte antigen 96 & Pro-inflammatory cytokines
1. Introduction
Our start point is that: inflammation is known pathogenesis of different patho-
physiological conditions and diseases affecting different body tissues whether acute 
or chronic. Every inflammation involves an immune response -innate and adap-
tive- that started with specific receptors called recognition receptors to identify 
stimuli/damage signal, activation of consequence inflammatory pathway/cascade, 
the release of inflammatory markers, and recruitment of inflammatory immune 
cells [1].
The innate immune response is initiated by either endogenous ligands acting as 
damage signals known as the damage-associated molecular pattern (DAMPs), or 
exogenous pathogenic ligands-that are accurately portion of the pathogenic micro-
organism- lead to the same fate; damage signals throughout pathogen-associated 
molecular patterns (PAMPs) [2]. These patterns alter the body of the cell and cause 
tissue injuries leading to massive necrosis that release intracellular component into 
surrounding, these components activate TLRs [3, 4]. These processes, which are 
both the mechanism and the net results of inflammations, infections, or ischemic 
injuries cause more, harm than the initial causes itself by improper stimulation of 
the immune response [3, 4].
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TLRs are a family of pattern recognition receptors (PPR), which also involves 
nucleotide oligomerization domain (NOD)-like receptors (NLR) and retinoic acid-
inducible gene I (RIG-I)-like receptors (RLR). They are located on cell membrane/
surface and nucleus, are responsible for the detection/recognition of the pathogen 
or intracellular damaged derived molecular signals to start immune response [1, 2].
These complicated inflammatory processes induced by the immune system 
are the “Classical typical scenario” involved in the majority of ischemic events, 
cancers, infectious and inflammatory diseases [4]. For further information about 
the immune system, Video 1 (https://youtu.be/8mEnyBdsrr8) can be shown 
on Armando Hasudungan YouTube channel [2] that would explain the innate 
 immunity link with TLRs.
2. Toll-like receptors
TLRs are PRR family involves 13 members that exist in mammals with 10 mem-
bers detected in the human genome [5, 6], depending on their similar morphology 
with Toll. Toll is a gene product that participate in both embryonic polarity develop-
ment and adult fly -antimicrobial response of the species Drosophila melanogaster 
[6, 7]. A 1996 study of this gene product linked the loss/gain of function to the 
insect’s susceptibility and immunologic response to fungal infections; increasing 
the temptation to seek for the amino acids sequence of the genome. This lead to the 
final identification of toll-like receptors in 1998 [4].
2.1 Toll-like receptors tissue expression and cellular distribution
TLRs are expressed in almost all body tissues involved in immunologic 
response as well as those exposed to external environments like the spleen, blood, 
lung & gastrointestinal tract [4, 8]. The particular cellular expression involves 
innate and adaptive immunity as well as different nonimmune cells. TLRs cel-
lular expression involves the white blood cells “the sentinel of the innate immune 
response”: microphages (MΦ) & mast cell (MC) “innate immune response keys”, 
dendritic cells (DCs) (primarily pathogenic detector of the adaptive immune 
response) [4, 6, 8, 9], endothelial cells, epithelial cells, fibroblast, glial cells, 
astrocytes, oligodendrocytes, etc. [1, 5, 8, 10].
Cellular expression of TLRs family members largely variable and mainly 
depends on the presence of active infections [8]; according to the same source, as 
ex., bacterial product & pro-inflammatory cytokines can induce the expression of 
TL3 while IL-10 blocks TLR4 expression. It has been found that TLR2 expression 
is more specifically involved in the gram-positive bacteria signaling [8]. TLRs are 
located either primarily to immune cell plasma membrane phospholipids including 
TLR 1, 2, 4, 5, 6, & 11 [3, 4, 8]; Or located at the endosomal and lysosomal phospho-
lipids where their extracellular domain (ECD) and its ligand-binding site project 
into the interior of the organelles like TLR 3, 7, 8, 9, 10 and 13 [2, 3, 10, 11].
2.2 Toll-like receptors biochemistry and Structure
TLRs are a type I integral transmembrane glycoprotein family of very conserved 
structure [5, 7], consist of 700–1100 amino acids [2, 4]. Their structure, shown in 
Figure 1 consist of 2 domains: an ECD that recognize ligands, consist of repetitive 
motifs rich with leucine and an intracellular domain (ICD) –called cytoplasmic- 
that maintain inflammatory signal consequence, the last consist of interleukin 
(IL)-1 receptor region called Toll/IL receptor (TIR) domain [12, 13].
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3. Toll-like receptors family members
TLRs involves 13 family members that exist in mammals with 10 members 
detected in the human genome [5, 6]. Human TLRs amino acids sequence allow a 
subfamily classification into the TLR2, TLR3, TLR4, TLR5, and TLR9 subfamilies. 
The TLR2 subfamily involves TLR1, 2, 6, and 10; the TLR9 subfamily involves TLR7, 
8, and 9 [14].
TLRs members can form homodimers/heterodimers among their same protein 
family or associates with an “outside TLR family” protein; both formations con-
tribute to their structural and functional diversity [4]. Homodimers are formed by 
TLR4 while TLR members 1, 2, and 6 like TLR1/2 or TLR2/6 dimers form heterodi-
mers [2, 3, 15–17]. TLRs members, their dimerization, cellular distribution, ligands, 
induced signaling pathway, and product are shown in Table 1; for further informa-
tion about TLRs, Video 2 (https://youtu.be/8mEnyBdsrr8) about TLR overview can 
be shown at Armando Hasudungan YouTube channel [18].
3.1 Toll-like receptors binding ligands
TLRs family members can recognize two types of associated molecular pat-
terns as their ligands, derived from pathogens or damaged organelles damaged 
structures.
3.1.1 PAMPs
PAMPs derived from pathogen [5, 19]; like gram-negative bacterial lipopolysac-
charides (LPS), gram-positive bacterial lipoteichoic acid (LTA) and peptidoglycan 
Figure 1. 
A representative structure of TLR. The conserved structural features of all TLRs consist of three critical 
components: (1) leucine-rich repeat (LRR) motif; (2) transmembrane helix; (3) intracellular TIR domain. 
The LRR structure is based on the model of TLR1-TLR2 heterodimer (Protein Data Bank, PDB, ID: 2z7x) 
interacting with six triacylated-lipopeptides, Pam3CysSerLys4 (Pam3CSK4), whereas the TIR domain 
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TLR8 Endosomes
Mo, MΦ, DC, MC
ssRNA,
Imidazoquinolines (R848)
ssRNA MyD88 IC, type1 IFN
TLR9 Endosomes
Mo, MΦ, DC, B, T
CpG DNA
CpG ODNs
Chromatin IgG complex MyD88 IC, type1 IFN
TLR10 Endosomes
Mo, MΦ, DC
profilin-like proteins MyD88 IC
Mo: monocytes, MΦ: macrophages, DC: dendritic cells, MC: Mast cells, B: B cells, T: T cells, IE: Intestinal epithelium, IC: Inflammatory cytokines [2]
Table 1. 
TLRs cellular expression, binding ligands, signal adaptor & production [2].
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(PGN), mycobacterial lipopeptides, yeast zymosan, viral and bacterial ribonucleic 
acid (RNA), and unmethylated cytosine phosphate guanine containing- (CpG) 
deoxyribonucleic acid (DNA) [20, 21].
3.1.2 DAMPs
DAMPs damaged organelles structures, extracellular matrix, cytosolic and 
nuclear proteins, Heat shock protein-60 (HSP-60) and HSP-70, hyaluronic acid 
fragments, and free fatty acids (FFA) [5, 22, 23]. They cause activation of the innate 
and inflammatory immune responses, epithelial regeneration, and sterile inflam-
mation control [6, 24].
4. Toll-like receptors signaling pathway
Upon TLRs recognition and binding to their ligands, they undergo conforma-
tional changes, dimerization as well as interaction with adaptor molecules passing 
series of intracellular signal transduction pathways that involve transcription fac-
tors NF-κB, IRFs, and mitogen-activated protein kinase (MAPK) activation. These 
pathways finally resulting in the secretion of pro-inflammatory mediators including 
nitric oxide (NO), CK- like tumour necrosis factor-alpha (TNF-α), IL-6 & IL-1β, 
chemokines (CC), and type I IFN [15, 21, 25, 26]. As shown in Figure 2.
4.1 Co-receptors
Co –receptors involved in TLRs signalling include Cluster differential 14 
(CD14) and Lymphocyte antigen 96 (MD-2). Both have a major role in TLR4 
activation after LPS recognition. CD14 is a glycophosphatidylinositol attached 
Figure 2. 
Signaling pathways of TLR. Surface and endosomal TLRs bind to adaptor molecules and co-receptors. Signal 
through Myd88 dependent/independent pathway ending with proinflammatory CK or type I IFN [12].
Innate Immunity in Health and Disease
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protein expressed on innate immune cells as macrophage and monocytes that 
function as co-receptor for both cell surface & endosomal expressed TLRs. 
Lymphocyte antigen 96 (MD-2), which is a cell membrane glycoprotein associ-
ated specifically with TLR4 ECD, and expressed at myeloid and endothelial 
cells [6, 13, 21, 26, 27].
4.2 Adaptor proteins and kinase molecules
TLRs signaling pathways involves four main adaptor protein molecules: MyD88, 
TIR domain-containing adaptor protein/MyD88 adaptor-like molecules (TIRAP) 
also called MAL, TIR domain-containing adaptor protein inducing interferon-β 
(TRIF), and TRIF related adaptor molecule (TRAM) [13, 21, 28]. TLRs signaling 
pathways involves activation of five TIR containing adaptor kinase molecules, like 
IL-1 receptor-associated kinase (IRAK) -1 and 4, TNF receptor-associated fac-
tor-6 (TRAF6), serine/threonine binding kinase (TBK)-1, MAPK, and inhibitor of 
kappa-B (IκB) kinase (IKK) [13, 28].
4.3 Transcription factors
There are three transcription factors involved in the TLRs signalling pathway 
including NF-κB, AP1, and IRF. NF-κB is an intracellular pleiotropic protein 
complex; it is responsible for gene regulation of proinflammatory CK, CC, adhe-
sion molecules, and cell cycle/survival regulating proteins as cyclin D1 and B cell 
lymphoma 2 (Bcl-2). AP1 is a dimer of both protein Jun and Fos families; that is 
associated with cell replication and survival regulation. Finally, the IRFs protein 
regulating IFNs, are responsible for signal stimulation via MyD88independent/
TRIF pathway [6, 13].
4.4 Intracellular signaling pathways
There are two intracellular signalling pathways for TLRs involve MyD88-
dependent/& MyD88-independent also called (TRIF-dependant) signal transduc-
tion pathway.
4.4.1 MyD88-dependent pathway
It is utilized by all TLRs but not TLR3 [21, 29]. This pathway activates the 
IRAKs, TRAF6, transforming growth factor (TGF)-β-activated kinase (TAK)-1 
and the IKK complex [15]. It causes the nuclear translocation of NF-κB and adaptor 
protein-1 (AP1) [28, 30], and ends with the secretion of CK like IL-6, IL-10, IL-12 
& TNF-α [16, 29]. MyD88 also stimulate the classical extracellular signal-regulated 
kinases (MAPK/ERK), phosphoinositide-3 (PI3), and Jun (N)terminal kinase 
(JNK) which stimulate the AP1 signalling pathway, and induce the interferon 
regulatory factor-7 (IRF7) ending with the release of type-I IFN or co-stimulatory 
molecules associated with the antimicrobial response by endosomal TLRs 3, 7, 8 
and 9 [13, 29, 31, 32].
4.4.2 MyD88-independent pathway
The main pathway of TLR3 and 4, involve TRIF signalling pathway activa-
tion which involves TRAF6 activation, results in inositol triphosphate-3 (IP3) 
phosphorylation and induction of IFN-β gene expression as well as activation of 
TRAF6 [21, 29].
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Surprisingly the same outcome was obtained from plasmatoid dendritic cells 
(pDCs) stimulated by TLR 7& 9 throughout the activation of the MyD88/IRF7 
dependent pathway [15, 33].
4.5 Unique pathways
TLR4 further utilizes TIRAP to activate MyD88 and TRAM to bridge the TRIF 
activation, which means that TLR4 uniquely utilizes both the MYD88 dependent 
and independent pathways [11, 21, 29].
As stated by S. Kiziltas et al. “TLR stimulation product is dependent on the 
nature of PAMPs, the activated TLR, the activated cell and the level of CK. 
Moreover, the chronically activated signalling pathway would possibly induce 
transcription of oncogenic factor; adding further complexation to the intracellular 
signalling for these receptors” [5, 13].
5. Toll-like receptors and pathophysiological disorders
TLRs play an important role in pathophysiological disorders due to their wide 
tissue distribution, their function as pattern recognition receptors that respond to 
variable bacterial and damage associated molecules, and involvement in multiple 
inflammatory signal pathways/& process all render TLRs being a major player in 
any inflammation-related disorder [4–6, 19, 22, 23, 34]. In addition, analysis of 
TLRs gene polymorphism in human disorders revealed an increased risk of bacte-
rial infection and sepsis as an example [34]. This section is a shortcut or summary 
to TLR involvement in different pathophysiological disorders rather than a full 
description section.
5.1 Toll-like receptors and pathophysiology of inflammatory oxidative stress
Inflammation is a common etiology of many disorders and disease including 
ischemic injuries, microbial infections, diabetes, arthritis and cancer [3, 4, 35]; 
still, any inflammatory process is triggered by damage signal recognized by pat-
tern receptors and induce activation of signaling pathways leading to the produc-
tion of pro-inflammatory markers and activation of immune cells [35]. These 
processes also induce the release of free radicals (FR) such as reactive oxygen 
species (ROS) and the activation of hypoxia-inducible transcription factor-1 
(HIF1), causing tissue stress and reduced tissue oxygen status, so-called tissue 
hypoxia. Hypoxia is believed to be a hallmark as well as a key trigger of inflam-
mation itself [35, 36].
Under normal conditions HIF1-α subunit (the inducible form of the heterodi-
mer protein HIF-1 transcription complex) [35], is controlled by hydroxylation of 
proline residue via prolyl hydroxylase enzyme, and breaking down via proteasome. 
However under inflammatory conditions LPS activate TLRs that stimulates nicotine 
amide adenine dinucleotide phosphate (NADPH) oxidase (Nox)-associated cross-
talk with the MAPK signaling pathways [36, 37], that causes proinflammatory CK 
& markers production thus increasing mitochondrial FR release like ROS causing 
more and more tissue stress. That causes HIF1- α activation; here HIF1- α protein 
inactivation process will be inhibited due to proline consumption, leading to HIF1-α 
accumulation in MΦ, DCs and other non-immune cells that exposed to hypoxia/ & 
non-hypoxic damage signals [38]. Furthermore, this would induce metabolic repro-
gramming of mitochondrial respiration causing succinate release, and production 
of IL-1β [35, 38].
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In dendritic cells, TLRs cause further stabilization of HIF1-α via release of 
NF-κB, which would further increase glucose uptake and render shifting of mito-
chondrial respiration to the anaerobic glycolytic pathway due to the increased 
oxygen demand versus the decreased supply [35, 36]. Finally result in disruption 
of the normal function of DCs, the primary pathogenic detector of the adaptive 
immune response; which undergo cellular maturation upon TLRS activation that 
results in further expression of co-stimulatory molecules, further production of 
pro-inflammatory CK & CC, and migration to lymph node so to present antigens to 
naïve T-cells [4, 35]. All these scenarios would further amplify the existing inflam-
mation and tissue damage [35].
HIF1-α is a transcription factor that responsible for cellular adaptive responses 
after exposure to injury/stress environment, including maintenance like controlling 
angiogenesis to improve blood vessel formation, shifting cellular mitochondria 
respiration to anaerobic glycolysis through improving cellular survival and cellular 
adhesion in oxidative stress environment’s [36]. In addition, it is the major control-
ler of phagocytes bactericidal capacity, and involved in myeloid cell-mediated 
inflammation, and is an essential factor for inhibition of myeloid cell apoptosis 
induced by LPS. The last point made it an important factor also in the TLR4 sig-
naling pathway [36, 38]. HIF1-α function as a double-edged sword, that mediate 
cellular adaptive to stress but progress disease status by the same time [38].
5.2 Toll-like receptors important role in the pathophysiological disorder
5.2.1 Central nervous system
TLRs are expressed in various central nervous system (CNS) cells predominantly 
in neurons, astrocytes, resident microglia, cerebral microvasculature, plexuses 
choroid, and leptomeninges. They are associated with the detection of- and regu-
lated by central DAMPs [33]. TLR4 is further upregulated centrally by glutamate via 
N-methyl-D-aspartate (NMDA) dependent mechanism and peripherally by nor-
adrenaline/β2 receptor, & corticotrophin-releasing factor. TLRs play an important 
role in restoring central homeostasis, physiology of stress-sensitive behaviour after 
injuries or diseases as multiple sclerosis, Alzheimer’s, and stroke [33].
In the experimental model of CNS, stress exposure revealed mRNA upregula-
tion and activation of TLRs in the brain frontal cortex after the stress is involved in 
the loss of neuronal plasticity and survival depending on the activation of NF-κB 
induced ROS production. Also resultant bacterial translocation from the gut to the 
systemic circulation and other organs such as the liver, spleen, and mesenteric lymph 
nodes; These circulating gram-negative bacteria are the major source of LPS, which 
can activate brain TLR4 through multiple pathways, including a neuroinflammatory 
response. This is partially explained by the theory known as leaky gut [11, 33].
In another experimental model of neurogenesis, TLR3 & 4 were found to act as 
down regulators, TLR3 deletion/loss of function was also linked to improved cogni-
tive function. The same reference state an opposed case in viral meningitis when 
TLR3 & 9 recruitment help to decrease neuronal injury and localize infection area 
and in Alzheimer disease where TLR2, 4, 5, 7 & 9 were suggested to improve disease 
progression by inhibiting amyloid plaque accumulation [1].
5.2.2 Respiratory system
TLR is thought to play a considerable role in several respiratory disorders 
starting from allergic rhinitis ending with severe inflammatory disorders like acute 
respiratory distress syndrome (ARDS), through their activation by the causative 
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inflammations derived by pulmonary oedema, trauma, sepsis & even drug overdose 
[9, 37]. In allergic rhinitis TLR2, 3, & 4 were found to be both upregulated by- and 
involved in-the causative inflammation [37].
TLR2 has the mainstay of involvement & determination in respiratory allergic 
disease due to considerable genetic variation. In asthma, an experimental study 
shows TLR2 induction by synthetic Pam3Cys triggers immune response & disease 
severity [37]. While in acute lung injury (ALI) & ARDS, TLR2 was found to be acti-
vated by Toll interacting protein (Tollip) [14]. TLR4 was found to increase asthmat-
ics severity & prevalence in paediatrics. TLR4 genetic polymorphism affects cluster 
differentials (CD)41–251 regulatory T cells (Tregs) which are activated by LPS, the 
same ligand of TLR4 itself. [2, 3, 37].
5.2.3 Cardiovascular system
An experimental model of doxorubicin and hydrogen peroxide-induced 
cardiac injury showed TLR2 to be involved in cardio myocytes apoptosis, besides 
TLR2 targeting suggested to be protective in septic cardiomyopathy [1]. In addi-
tion, murine models revealed cardiac tissue expression of TLR4 increased after 
hypertension, myocardial ischemia, maladaptive left ventricular hypertrophy, and 
angiotensin II (AngII) infusion participating in vascular remodelling & stiffness, 
endothelial dysfunction, increase myocardial infarction (MI) size & susceptibility. 
While Human studies revealed the same in patients with unstable angina, MI, heart 
failure, atherosclerosis & myocarditis [9, 27, 39–41].
TLR4 expression & signalling was increased in patients’ monocytes during 
attacks of unstable angina & MI [37]. In the experimental model & human vascular 
inflammation, TLR4 was found to increase the production of CK, CC as well as 
increase TLR2 expression. In the early stage of the atherosclerotic lesion, TLR4 
mRNA protein was detected & MyD88 -the mainstay of TLR signalling pathway- 
gene deficiency was linked to decrement in CK, CC & lipid content production, as 
well as in atherosclerotic lesion size. The same reference stated that TLR2 genetic 
polymorphism was linked to increased coronary artery stenosis, while TLR7 & 8 
was involved in cardiac inflammation caused by the Coxsackie virus [37].
5.2.4 Gastrointestinal system
The liver is the major organ that deals with gut-derived endotoxin, exposed 
by portal circulation [13, 42]. This continuous exposure would trigger frequent 
activation of the hepatic innate immune system; which contributes to the induction 
of inflammation in acute hepatic injuries, which means involvement of TLRs in 
the induction of inflammation [13]. Pathogenic suppression/& inhibition of TLRs 
found to mediates chronic hepatic injuries/disorders like hepatitis, fibrosis, alco-
holic liver injuries, ischemia/reperfusion injury, and carcinoma [13, 28].
In Paracetamol human hepatotoxicity, endogenous chemical injury derives 
extracellular matrix (ECM) the ligand that activates TLR4 to release TNF-α, induce 
inducible nitric oxide synthase (iNOS), peroxynitrite, glutathione depletion, so that 
will amplify immune response, sequestering leukocytes, increase serum hyaluronic 
acid, causing steatosis, necrosis, and hepatic congestion [16].
Hepatitis viral nucleic acid & proteins are the ligands detected by TLR3, 7, 8, 
& 9. Starting with hepatitis B virus (HBV), in vitro activation of TLR1, 2, 3, 4, 5, 
6, 7, 8, & 9 result in the release of IFN which inhibit HBV DNA replication and 
RNA transcription. Whilst HBV itself downregulates the expression of TLR1, 2, 
4, & 6, this limits their antiviral effect or even renders them nugatory [28]. This 
downregulation of TLRs is attributed to the presence of HBV e antigen (HBeAg) 
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during acute infection. About hepatitis C (HCV), its core protein activates TLR 1, 
2, 4 & 6, which are supposed to produce antiviral IFNs as well as increased hepatic 
inflammation. The same effect is presumed by TLR 3 & 4 in HBV is achieved here 
to produce IFN-β [28].
In alcoholic liver disease (ALD), alcohol mainstay effects are to increase gut 
mucosal permeability to LPS, modification of gut flora, reducing endotoxin clear-
ance rate, and increasing hepatic endotoxin level [16]. These scenarios lead to 
higher expression of TLR1, 2, 4, 6 & 9 by both parenchymal and non-parenchymal 
cells, activating their pathway and release of inflammatory mediators, this process 
observed in the chronic alcohol experimental model [28, 29]. While a patient with 
cirrhosis expresses a high level of TNF-α, IL-1β, & IL-6, as well as chronic endotox-
emia, recurrent bacterial infection [16]. Finally, the process of hepatic regeneration 
depends on the interplay between the immune system and non-parenchymal cell, 
which involves activation of TLRs/MyD88 pathway, here the bulky activation of 
TLRs, would inversely affect the regeneration process, which indicates that the 
extent of such activation is essential for hepatic regeneration. TLR2, 4 & 9 reported 
no important role in liver regeneration process [28, 43].
Both human patients and experimental models of diabetes linked the active TLR 
to the progression of diabetes complication throughout the activation of NF-κB 
signalling in adipose tissue MΦ due to high level of plasma FFA associated with 
obesity & diabetes type 2 (T2DM) [44].
In vivo & in-vitro studies performed by Zhang N. et al. revealed that TLR 2 & 4 
activation in insulin target tissues as the liver, adipose tissue & immune cells linked 
them with insulin resistance. The first suggests that high TLRs loss of function or 
genetic modification protects against high FFA level resulted from large mass adi-
pose tissue secreting non-esterified free fatty acids & reduction of their clearance/
oxidation which disturbs gut permeability to LPs [45].
TLR4 resultant inflammation associated with activation IKK, MAPK, JNK, and 
p38 pathways would further increase insulin receptor substrate-1 (IRS1) serine 
phosphorylation thus decrease insulin receptor’s signal transduction [31, 45]. 
Furthermore, TLR4-MyD88 signalling pathway activation was suggested throughout 
developmental researches for several anti-hyperlipidemic medications, while TLR1, 
2, 3 & 7 were triggering both host immune defence and/autoimmune response that 
aggravate diabetic state [37].
5.2.5 Urinary system
TLRs expression in renal tube epithelial lining render their activation to be 
essential in renal vascular remodelling, endothelial dysfunction in multiple 
renal disorders like acute kidney injury (AKI), solid organ transplant, glomeru-
lonephritis, ischemic/reperfusion injury (I/R injury) & diabetic renal disorders 
[27, 44]. Experimental streptozocin induced diabetic model revealed podcy-
topathy & fibrosis regression after TLR4 knocking out, as they are expressed by 
podocytes & decreased diabetic nephropathy after TLR2 knocking out [46, 47]. 
TLR4 gene polymorphism was linked to prostate cancer among gene clusters of 
TLR1, 6 & 10 [37].
6. Toll-like receptors as therapeutic targets
TLRs, as the primary receptor for many ligands that trigger innate & adap-
tive immune response, with complex signaling pathways involving many adaptor 
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molecules & co-receptors seem interesting for therapeutic target development. 
Synthetic agonist, antagonist and even naturalized antibodies could modify TLRs 
signaling to make them attractive targets for the management of different inflam-
matory disease. For example at 2013, Savva and Roger enlisted around 32 clinical 
trials at different phases for TLRs agonist/antagonist agent for the management of 
sepsis and infectious disease, these trials include even the antimalarial old agent 
chloroquine [28, 34].
6.1 Toll-like receptors 1 and 2
TLR1/2 heterodimers were found to be increased in patients with atherosclerotic 
lesions, while administration of TLR1/2 agonist aggravates disease status, also TLR2 
inhibition was suggested as diabetes and cardiovascular disorders therapy besides 
statins & thiazolidinedione by anti-inflammatory action [9]. Pam2/3CSK4 TLR2 
ligands covalently linked to CD8+ or B-cell epitopes associated peptides were found 
to enhance therapeutic response in tumour models, by stimulating TLR2 induced 
T-cell activation [15]. A 3 component carbohydrate-based cancer vaccine involved 
TLR2 activator that mediates humoral immune response against tumour-induced 
glycopeptide antigens by affecting the maturation of cellular component of the 
innate immune system (DC & natural killer cells), furthermore cancer treatment 
with chimers of anti-tumour antibodies and small molecule agonist of TLR2 would 
alleviate disease progression [9].
6.2 Toll-like receptor 3
Since high synovial expression of TLR3 in RA patients was found, one scenario 
for rheumatoid arthritis and possibly bone malignancy is to inhabit the TLR3 
pathway via the RNA synthetic analogue Polyinosine-polycytidylic acid (poly (I:C) 
that affect monocyte –osteoclast cellular differentiation [9].
6.3 Toll like receptor 4
Various TLR4 antagonist was developed as a therapeutic agent, starting with the 
peptide P13- an inhibitor of TIR domain signalling pathway- that was found to ame-
liorate inflammatory response and improve surviving in a TLR4-mediated hepatic 
injury of murine model [16]. In addition, Lipid A mimetics E5564 and CRX526 
bind to TLR4-MD2 complex showing valuable inhibition of pro-inflammatory 
cytokine IL-1 and TNF-α production in LPS treated animal models as well as septic 
shock patients in phase III clinical trial [9, 16, 29]. TLR4 inhibition was suggested 
as the scenario for treatment of thrombosis, atherosclerosis & vascular restenosis 
throughout coating TLR4 or MyD88 with inhibitory compound, small molecule 
antagonist, then by giving viral vectors that express antisense gene to TLR4 RNA 
[9], and finally TLR4/MD2/anti-Human IgG (Fc specific) (IgG-Fc) fusion protein 
inhibitor of NF-κB and JNK activation provides interesting biologic therapy for 
liver fibrosis, alcoholic and non-alcoholic steatohepatitis by decreasing IL-6 and 
monocyte Chemoattractant Protein-1(MCP-1) production [16].
Another TLR4-synergizer Fc/fusion protein and TL4 ligand α-1 acid glyco-
protein were found to inhibit LPS-induced activation of hepatic MΦ by blocking 
the triggering receptor expressed on myeloid cells-1 (TREM1), and boosting the 
anti-inflammatory immune response. Other theoretically interesting scenarios 
involving the I.V administration of monophosphoryl lipid A derivatives as 2 adult 
HBV vaccine in treating viral hepatitis [13, 15, 16].
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6.4 Toll-like receptors 5 and 7
One possible scenario for cancer immunotherapy involved TLR5 binding to flagel-
lin that can turn the tolerogenic DCs into active antigen-presenting cells (APC) [9].
Isatoribine, a TLR7 agonist administered I.V was found to decrease viral load 
with a moderate adverse effect profile in HCV patients. In addition, IGS-9620 
that was experimentally assessed on the HBV animal model was found to decrease 
HBVs antigen (HBsAg) level in serum, HBV viral load as well as IFN-α in dose 
dependent-manner [15, 29]. Note that some TLR7 targeting therapies were 
approved by Food and Drug Administration (FDA) like imiquimod, TLR7-immune 
response modifier that was approved since 1997 for treatment of superficial skin 
malignant melanoma & genital warts by increasing cellular production of CK like 
IFN, IL-6 & TNF [9].
6.5 Toll-like receptor 9
Selective TLR9 agonists like 1018 ISS (immunomodulatory sequences) that 
contain repeated CpG motifs were found to modulate the TLR9 signalling pathway 
involved in HBV infection and have been tested in phase III clinical trials. Another 
agonist IMO-2055 was under assessment in 2011 for oncologic disease as well as 
IMO-2125 which was found to maintain the high level of IFN was under assessment 
as a possible therapy to HCV patients. The TLR9 intracellular signalling inhibitors 
ST2825 and RO0884 designed to block IRAK1 &4/MyD88 singling pathway caused 
inhibition of the NF-κB, IL-1β, and TNF-α activation as well as decreased hepatic 
IL-6 secretion [9, 15, 29].
7. Conclusions
Medical and pharmacological development is focusing on the molecular level, 
in all aspects including analytical, physiological, pharmacological and even genetic 
aspects. Understanding immune response is thus important subject, furthermore, 
the target receptors which damage signals bind to, their signaling pathways end 
products will tell what possible immune response happened to human body. Toll-
like receptors are those targets, the family of integral transmembrane glycoprotein 
expressed intracellularly or at cellular surface, considered main component and 
link between innate and adaptive immune response, which can induce signaling 
pathways involving four main adaptor molecules that initiate divaricated steps end-
ing with inflammatory cytokines. These pathways could be involved in any inflam-
matory process/disorders and thus seems interesting targets for pharmacological 
intervention; all these steps bring us back to the bullet that explodes all these events 
in the body, the immune system.
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Abbreviations and nomenclature
AKI Acute kidney injury
ALD Alcoholic liver disease




ARDS Acute respiratory distress syndrome
Bcl-2 B cell lymphoma 2
CC Chemokine
CD14 Cluster differential 14
CK Pro-inflammatory cytokines
CpG Cytosine phosphate guanine




FFA Free fatty acids
FR Free radicals
HBeAg HBV e antigen
HBsAg HBV s antigen
HIF1 Hypoxia-inducible factor-1
HSP Heat shock protein
I/R injury Ischemic/reperfusion injury
ICD Cytoplasmic domain
IFN Type-I interferon
IgG-Fc Anti-Human IgG (Fc specific)
IKK Inhibitor of kappa-B (IκB) kinase
IL Interleukin
iNOS Inducible nitric oxide synthase
IP3 Inositol triphosphate-3
IRAK IL-1 receptor-associated kinase
IRF Interferon regulatory factor
IκB Inhibitor of kappa-B




MAPK Mitogen-activated protein kinase
MAPK/ERK Extracellular signal-regulated kinases
MC Mast cell
MCP-1 Monocyte Chemoattractant Protein-1
MD-2 Lymphocyte antigen 96
MI Myocardial infarction
mRNA Messenger ribonucleic acid
MyD88 Myeloid differential88
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MΦ Macrophage
NADPH nicotine amide adenine dinucleotide phosphate
NLR nucleotide oligomerization domain (NOD)-like receptors
NO Nitric oxide
NOD nucleotide oligomerization domain
Nox NADPH oxidase
Pam3CSK4 Pam3CysSerLys4
PAMPs Pathogen-associated molecular patterns




PRRs Pattern recognition receptors
RIG-I retinoic acid-inducible gene I
RLR retinoic acid-inducible gene I (RIG-I)-like receptors
ROS Reactive oxygen species
T2DM Diabetes type 2
TAK Transforming growth factor (TGF)-β-activated kinase
TBK-1 Serine/threonine binding kinase
TF Transcription factors
TGF Transforming growth factor
TIR Toll/IL-receptor
TIRAP/MAL TIR domain-containing adaptor protein/MyD88 adaptor like
TLRs Toll-like receptors
TNF-α Tumour necrosis factor-alpha
Tollip Toll interacting protein
TRAF6 TNF receptor-associated factor-6
TRAM TRIF related adaptor molecule
Tregs Regulatory T cells
TREM1 Triggering receptor expressed on myeloid cells-1
TRIF TIR domain-containing adaptor protein inducing interferon-β
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